Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Ranjana H. Advani, Michael J. Dickinson, Christopher P. Fox, Brad Kahl, Alex F. Herrera, Georg Lenz, Yuqin Song, Rong Tao, Qingqing Cai, Tae Min Kim, Michelle Doral, Derrick Kaufman, Leonardo Roque Pereira, Aurelien Berthier, Franck Morschhauser

Blood (2024) 144 (Supplement 1): 1718.1.

https://doi.org/10.1182/blood-2024-194000

Published: 2024

Journal Articles

Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

Blood (2024) 144 (Supplement 1): 67.

https://doi.org/10.1182/blood-2024-204264

Published: 2024

Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Blood (2024) 144 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2024-201730

Published: 2024

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Blood (2024) 144 (Supplement 1): 990.

https://doi.org/10.1182/blood-2024-200096

Published: 2024

Journal Articles

Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

Blood (2024) 144 (Supplement 1): 1631.

https://doi.org/10.1182/blood-2024-200018

Published: 2024

Journal Articles

CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Blood (2024) 144 (Supplement 1): 644.

https://doi.org/10.1182/blood-2024-201406

Published: 2024

Journal Articles

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Blood (2024) 144 (Supplement 1): 865.

https://doi.org/10.1182/blood-2024-194333

Published: 2024

Journal Articles

Predicting Risk of Infection in Patients Receiving CAR-T for Aggressive Lymphoma: A Study Exploring the Utility of Immune Profiling

Gemma K Reynolds, Lewis Williams, Mary Ann Anderson, Mark R Dowling, Adrian Minson, Michael J. Dickinson, Karin A Thursky, Simon J Harrison, Monica A Slavin, Marcel Doerflinger, Benjamin W Teh

Blood (2024) 144 (Supplement 1): 7136.

https://doi.org/10.1182/blood-2024-203133

Published: 2024

Journal Articles

Longitudinal Cytokine Expression in Aggressive Lymphoma Patients Treated with CAR-T: Applications of Immune Profiling to CAR-T

Gemma K Reynolds, Lewis Williams, Mary Ann Anderson, Mark R Dowling, Adrian Minson, Michael J. Dickinson, Karin A Thursky, Simon J Harrison, Monica A Slavin, Marcel Doerflinger, Benjamin W Teh

Blood (2024) 144 (Supplement 1): 7135.

https://doi.org/10.1182/blood-2024-202836

Published: 2024

Journal Articles

Cognitive and Psychological Recovery from the Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Valeriya Kuznetsova, Harsh Oza, Hannah Rosenfeld, Carmela Sales, Sam van der Linde, Izanne Roos, Stefanie Roberts, Fiore D'Aprano, Samantha M. Loi, Mark R Dowling, Michael J. Dickinson, Tomas Kalincik, Simon J Harrison, Charles B. Malpas, Mary Ann Anderson

Blood (2024) 144 (Supplement 1): 7240.

https://doi.org/10.1182/blood-2024-202851

Published: 2024

Journal Articles

A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics

Blood (2024) 144 (Supplement 1): 582.

https://doi.org/10.1182/blood-2024-204930

Published: 2024

Journal Articles

BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL

Blood (2024) 144 (Supplement 1): 3123.

https://doi.org/10.1182/blood-2024-205544

Published: 2024

Journal Articles

Global Access to Chimeric Antigen Receptor (CAR) T-Cell Therapies: Health Technology Assessment (HTA) of CAR T in G7 Countries and Australia

Alex Y Ge, William B Feldman, Martin F Kaiser, Kai Rejeski, Gloria Iacoboni, Michael J Dickinson, Aaron S Kesselheim, Edward R Scheffer Cliff

Blood (2024) 144 (Supplement 1): 3659.

https://doi.org/10.1182/blood-2024-208943

Published: 2024

Journal Articles

Real-World Outcomes of Patients with High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements Treated in the Contemporary Era

Victor S. Lin, Sean Harrop, Sean J. McKeague, Rory Bennett, Adrian Minson, Divya V. Somasekharannair, Edward Chew, Cameron Snell, Stephen Lade, Philip A. Thompson, John F. Seymour, Michael J. Dickinson, Mary Ann Anderson

Blood (2024) 144 (Supplement 1): 1700.

https://doi.org/10.1182/blood-2024-207849

Published: 2024

Journal Articles

Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience

Hamish W Scott, Mark R Dowling, Daniel Garcia, Samantha van der Linde, Nicole O'Leary, Brydon Panozzo, Adrian Minson, James A Kuzich, Aaron Jun Ning Wong, Michael S Hofman, Monique Youl, Belinda Campbell, Michael Patrick Macmanus, Philip A. Thompson, Mary Ann Anderson, John F. Seymour, Michael J Dickinson, Simon J Harrison

Blood (2024) 144 (Supplement 1): 4511.

https://doi.org/10.1182/blood-2024-209767

Published: 2024

Journal Articles

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Blood (2017) 130 (Supplement 1): 1377.

https://doi.org/10.1182/blood.V130.Suppl_1.1377.1377

Published: 2017

Journal Articles

Discovery of Candidate Predictors of Response to Tazemetostat in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Using NGS Technology on ctDNA Samples Collected Pre-Treatment

Blood (2017) 130 (Supplement 1): 4013.

https://doi.org/10.1182/blood.V130.Suppl_1.4013.4013

Published: 2017

Journal Articles

Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients

Blood (2017) 130 (Supplement 1): 2745.

https://doi.org/10.1182/blood.V130.Suppl_1.2745.2745

Published: 2017

Journal Articles

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Benjamin Lanza, Giovanni Martinelli, Karen W.L. Yee, MD, Lori Jukofsky, Bernhard Reis, PhD, Steven Blotner, PhD, Mark W. Drummond, PhDMD, Norbert Vey, MD PhD, Karen Seiter, MD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Kevin R. Kelly, MD PhD, Margaret Kasner, MD, Michel Theron, PhD, Jeffrey M. Venstrom, Steven Middleton, PhD, Lin-Chi Chen, MD PhD, Nelson Kinnersley, Gwen Nichols, MD, William E. Pierceall, PhD

Blood (2016) 128 (22): 2843.

https://doi.org/10.1182/blood.V128.22.2843.2843

Published: 2016

Journal Articles

Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Combination with Azacitidine (AZA) for Primary Treatment of Myelodysplastic Syndromes (MDS) Patients with Thrombocytopenia: Outcomes from the Randomized, Placebo-Controlled, Phase III Support Study

Michael J. Dickinson, MBBS, FRACP, FRCPA, Honor Cherif, Pierre Fenaux, Moshe Mittleman, Amit Verma, MD, Maria Socorro O Portella, MD, Paul Burgess, Uwe Platzbecker, MD

Blood (2016) 128 (22): 163.

https://doi.org/10.1182/blood.V128.22.163.163

Published: 2016

NARROW

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Predicting Risk of Infection in Patients Receiving CAR-T for Aggressive Lymphoma: A Study Exploring the Utility of Immune Profiling

Longitudinal Cytokine Expression in Aggressive Lymphoma Patients Treated with CAR-T: Applications of Immune Profiling to CAR-T

Cognitive and Psychological Recovery from the Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL

Global Access to Chimeric Antigen Receptor (CAR) T-Cell Therapies: Health Technology Assessment (HTA) of CAR T in G7 Countries and Australia

Real-World Outcomes of Patients with High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements Treated in the Contemporary Era

Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Discovery of Candidate Predictors of Response to Tazemetostat in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Using NGS Technology on ctDNA Samples Collected Pre-Treatment

Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Combination with Azacitidine (AZA) for Primary Treatment of Myelodysplastic Syndromes (MDS) Patients with Thrombocytopenia: Outcomes from the Randomized, Placebo-Controlled, Phase III Support Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only